HENRY TOYIN AKINBI
Medical Practice in Cincinnati, OH
License number
Pennsylvania MD044057L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Cincinnati, OH 45220
Pennsylvania
Pennsylvania
Personal information
See more information about HENRY TOYIN AKINBI at radaris.comName
Address
Phone
1118 Chatham Ct, Cincinnati, OH 45215
346 Fleming St, Wyoming, OH 45215
1118 Chatham Ct, Cincinnati, OH 45215
Professional information
Henry T Akinbi, Cincinnati OH
Specialties:
Neonatal Medicine
Address:
3333 Burnet Ave SUITE 4058, Cincinnati 45229
(513) 636-4830 (Phone), (513) 636-7868 (Fax)
Cincinnati Office
3333 Burnet Ave, Cincinnati 45229
(513) 636-4751 (Phone), (513) 636-8145 (Fax)
(513) 636-4830 (Phone), (513) 636-7868 (Fax)
Cincinnati Office
3333 Burnet Ave, Cincinnati 45229
(513) 636-4751 (Phone), (513) 636-8145 (Fax)
Certifications:
Pediatrics, 1991, Perinatal Medicine & Neonatal Medicine, 2003
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Ife / Faculty of Health Sciences
Children's Hospital Philadelphia
Moses H Cone Mem Hospital
University Of Nc Hosps
University of Ife / Faculty of Health Sciences
Children's Hospital Philadelphia
Moses H Cone Mem Hospital
University Of Nc Hosps
Henry T Akinbi, Cincinnati OH
Specialties:
Neonatal-Perinatal Medicine Specialist
Address:
3333 Burnet Ave, Cincinnati, OH 45229
Education:
Bachelor of Medicine, Bachelor of Surgery
Board certifications:
American Board of Pediatrics Sub-certificate in Neonatal-Perinatal Medicine (Pediatrics)
Lysozyme Fusion Proteins In Infections
US Patent:
5993809, Nov 30, 1999
Filed:
Nov 18, 1998
Appl. No.:
9/193877
Inventors:
Timothy Edward Weaver - Loveland OH
Henry Toyin Akinbi - Cincinnati OH
Henry Toyin Akinbi - Cincinnati OH
Assignee:
Children's Hospital Medical Center - Cincinnati OH
International Classification:
A61K 3816, A61K 3843, A61K 3847
US Classification:
424 9461
Abstract:
A method and composition for prophylaxis and/or treatment of bacterial infections, particularly bacterial respiratory infections. A fusion protein of lysozyme and the carboxyl terminal propeptide of surfactant protein-B (SP-B) with the preceding ten amino acids of the mature SP-B peptide is administered in a pharmaceutically acceptable medium to an individual. The fusion protein may be selected so as to deliver it to a target infection site, such as the lungs or gastrointestinal tract. The method and composition eliminates problems associated with conventional antibiotic treatments, such as inefficacy and promotion of antibiotic resistant bacterial strains.